TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorThird Affiliated Hospital, Sun Yat-Sen University
About this trial
The present study aimed to assess the effectiveness of the combination treatment of Atezolizumab/Bevacizumab, transcatheter arterial chemoembolization (TACE) and I-125 Seeds Brachytherapy (TACE-AB-I) in patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). The investigators confirmed that the combination therapy yielded better survival data than the combined administration of Atezolizumab/Bevacizumab and TACE (TACE-AB) in patients with advanced HCC and Type I/II PVTT (Based on Cheng's PVTT classification).
Eligibility criteria
Qualifiers
Age between18 and 75 years;
Has a diagnosis of HCC confirmed by radiology, histology, or cytology;
Type I PVTT or type II PVTT;
Child-Pugh class A;
Disqualifiers
Diffuse HCC;
Cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, and mixed hepatocellular/cholangiocarcinoma subtypes (confirmed by histology, or pathology) are not eligible;
Evidence of extrahepatic spread (EHS);
Any condition representing a contraindication to TACE or I-125 seeds brachytherapy as determined by the investigators;
Trial design
Treatments tested in this trial
- I-125 Seeds Brachytherapy in PVTT
- Transcatheter arterial chemoembolization
- Atezolizumab plus Bevacizumab
Treatment groups
234 Participants
are divided into 2 treatment groupsSponsors and collaborators
Third Affiliated Hospital, Sun Yat-Sen University
Lead sponsor
Sun Yat-Sen University Cancer Center
Collaborator
Fifth Affiliated Hospital, Sun Yat-Sen University
Collaborator
Second Affiliated Hospital of Guangzhou Medical University
Collaborator
Maoming People's Hospital
Collaborator
Shandong Province Third hospital
Collaborator
Source ClinicalTrials.gov